RESEARCH-USE BIOSIMILAR ANTIBODY
Seniprutug
Antibody fragment · Not specified
Seniprutug (BCD-180) is a humanized monoclonal antibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9+ T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis.
TARGETTRBV9
YAntibody fragment
CATALOGSC-BS-173
CATALOG NUMBERSC-BS-173
MOLECULAR WEIGHTApprox. 146.42 kDa
PRODUCT FORMATAntibody fragment
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Seniprutug (BCD-180) is a humanized monoclonal antibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9+ T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis.
Seniprutug is a recombinant research-use antibody directed against TRBV9.